Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies

Oncology Reports

Volumn 20, Issue 2, 2008, Pages 463-467

  Reinhard, Harald ^a   Schmidt, Andrea ^b   Furtwängler, Rhoikos ^b   Leuschner, Ivo ^c   Rübe, Christian ^b   Schweinitz, Dietrich Von ^d   Zoubek, Andreas ^e   Niggli, Felix ^f   Graf, Norbert ^b  

^a Asklepios Clinic   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e ST ANNA CHILDREN S HOSPITAL   (Austria)

^f Division of Metabolism Childrens' Hospital Zürich   (Switzerland)

Author keywords

Nephroblastoma; Prognostic factors; Relapses; Risk groups; SIOP patients

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN;

AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LOCAL METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; SEX DIFFERENCE; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; WILMS TUMOR;

EID: 48749093491     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000029     Document Type: Article

References (19)

1. Grundy P, Breslow N, Green DM, et al: Prognostic factors for children with recurrent Wilms' tumor: results from the second and third National Wilms' Tumor Study. J Clin Oncol 7: 638-647, 1989.
2. Miser JS and Tournade MF: The management of relapsed Wilms tumor. Hematol Oncol Clin North Am 9: 1287-1302, 1995.
3. Campbell AD, Cohn SL, Reynolds M, Seshadri R, Morgan E, Geissler G, Rademaker A, Marymount M, Kalapurakal J, Haut PR, Duerst R and Kletzel M: Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. J Clin Oncol 22: 2885-2890, 2004.
4. Pein F, Michon J, Valteau-Couanet D, Quintana E, Frappaz D, Vannier JP, Philip T, Bergeron C, Baranzelli MC, Thyss A, Stephan JL, Boutard P, Gentet JC, Zucker JM, Tournade MF and Hartmann O: High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J Clin Oncol 16: 3295-3301, 1998.
5. Kremens B, Gruhn B, Klingebiel T, Hasan C, Laws HJ, Koscielniak E, Hero B, Selle B, Niemeyer C, Finckenstein FG, Schulz A, Wawer A, Zintl F and Graf N: High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant 30: 893-898, 2002.
6. Green DM, Cotton CA, Malogolowkin M, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PR, Grundy PE, D'Angio GJ, Beckwith JB, Shamberger RC, Haase GM, Donaldson M, Weetman R, Coppes MJ, Shearer P, Coccia P, Kletzel M, Macklis R, Tomlinson G, Huff V, Newbury R and Weeks D: Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 48: 493-499, 2007.
7. Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I and de Kraker J: SIOP Nephroblastoma Scientific Committee: Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 38: 79-82, 2002.
8. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 54: 457-481, 1958.
9. Cox DR: Regression models and life tables (with discussion). JR Stat Soc 34: 187-220, 1972.
10. Pein F, Tournade MF, Zucker JM, Brunat-Mentigny M, Deville A, Boutard P, Dusol F, Gentet JC, Legall E, Mechinaud F, et al: Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor-a phase II study by the French Society of Pediatric Oncology. J Clin Oncol 12: 931-936, 1994.
11. Marina MN, Wiliams JA, Meyer WH, et al: Refining therapeutic strategies for patients with resistant Wilms' tumor. Am J Ped Hematol Oncol 16: 296-300, 1994.
12. Bergeron C, Iliescu C, Thiesse P, Bouvier R, Dijoud F, Ranchere-Vince D, Basset T, Chappuis JP, Buclon M, Frappaz D, Brunat-Mentigny M and Philip T: Does nephroblastomatosis influence the natural history and relapse rate in Wilms' tumour? A single centre experience over 11 years. Eur J Cancer 37: 385-391, 2001.
13. Kalapurakal JA, Li SM, Breslow NE, Beckwith JB, Macklis R, Thomas PR, D'Angio GJ, Kim T, de Lorimier A, Kelalis P, Shochat S, Ritchey M, Haase G, Hrabovsky E, Otherson HB, Grundy P and Green DM: National Wilms' Tumor Study Group: Influence of radiation therapy delay on abdominal tumor recurrence in patients with favorable histology Wilms' tumor treated on NWTS-3 and NWTS-4: a report from the National Wilms Tumor Study Group. Int J Radiat Oncol Biol Phys 57: 495-499, 2003.
14. Shamberger RC, Guthrie KA, Ritchey ML, et al: Surgery-related factors and local recurrence of Wilms Tumor in National Wilms Tumor Study 4. Ann Surg 229: 292-297, 1999.
15. Kullendorf C-M: Relapses in Wilms tumour. Pediatr Surg Int 19: 635-638, 2003.
16. Dome J, Liu T, Krasin M, et al: Improved survival for patients with recurrent Wilms tumor: The experience at St. Jude Children's Research Hospital. J Ped Hematol Oncol 24: 192-198, 2002.
17. Groot-Loonen JJ, Pinkerton CR, Morris-Jones PH and Pritchard J: How curable is relapsed Wilms' tumour? The United Kingdom Children's Cancer Study Group. Arch Dis Child 65: 968-970, 1990.
18. Pein F, Rey A, de Kraker J, Ludwig R, Pötter R and Godzinsky J: Multivariate Analysis of Adverse Prognostic Factors (APF) in Children with recurrent Wilms' tumor (WT) after initial treatment according to SIOP-6 or SIOP-9 strategies. Med Ped Oncol 33: 170, 1999.
19. Abu-Ghosh AM, Krailo MD, Goldman SC, Slack RS, Davenport V, Morris E, Layer JH, Reaman GH and Cairo MS: Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann Oncol 13: 460-469, 2002.